Publications by authors named "David Monteith"

Claim this Profile
A
Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Claire L Smith, Yan Jin, Eyas Raddad, Terry A McNearney, Xiao Ni, David Monteith

Pharm Stat· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.
David Monteith, Emily C Collins, Corinne Vandermeulen, Anne Van Hecken, Eyas Raddad

Front Pharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional deposition of mometasone furoate nasal spray suspension in humans.
Samir A Shah, Robert L Berger, John McDermott, Pranav Gupta, David Monteith

Allergy Asthma Proc· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model.
Steve Vermeersch, Robert J Benschop, Anne Van Hecken, David Monteith, Victor J Wroblewski

J Pharmacol Exp Ther· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.
Jeremy R Graff, Bruce W Konicek, Thomas M Vincent, Rebecca L Lynch, David Monteith

J Clin Invest· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro assays and biomarkers for drug-induced phospholipidosis.
David K Monteith, Ryan E Morgan, Bartley Halstead

Expert Opin Drug Metab Toxicol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinical flow cytometric biomarker strategy: validation of peripheral leukocyte phospholipidosis using Nile red.
Bartley W Halstead, Craig M Zwickl, Ryan E Morgan, David K Monteith, Craig E Thomas

J Appl Toxicol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals.
Mohammed Islaih, Bartley W Halstead, Ibrahim A Kadura, Baohui Li, Jaclyn L Reid-Hubbard, David K Monteith

Mutat Res· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury.
Lilit Masarjian, Ann de Peyster, Arthur A Levin, David K Monteith

Oligonucleotides· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.
Kyle W Sloop, Julia Xiao-Chun Cao, Angela M Siesky, Hong Yan Zhang, Diane M Bodenmiller, David K B Monteith

J Clin Invest· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.
Rosie Z Yu, Richard S Geary, David K Monteith, John Matson, Loanne Truong

J Pharm Sci· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis